Regeneron Pharmaceuticals announced updated five-year follow-up results from the pivotal Phase 3 EMPOWER-Lung 3 trial evaluating Libtayo (cemiplimab) in combination with platinum-based chemotherapy as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) without EGFR, ALK or ROS1 aberrations. The results, presented during a late-breaking mini-oral session at the IASLC 2025 World Conference on Lung Cancer (WCLC), underscore the long-term survival benefits of adding Libtayo to chemotherapy in this patient population.

“The EMPOWER-Lung 3 trial continues to demonstrate the sustained survival benefit of Libtayo plus chemotherapy in advanced NSCLC, even beyond five years of follow-up,” said Ana Baramidze, M.D., Ph.D., Head of Clinical Research Department at Todua Clinic, Tbilisi, Georgia.

“These long-term data highlight the significant clinical impact of Libtayo across diverse patient subgroups, including those with squamous histology, where we saw a median overall survival of 22.3 months. Collectively, the findings reinforce Libtayo’s value as both a monotherapy and in combination with chemotherapy for patients with advanced disease.”

These results from EMPOWER-Lung 3 build on previously presented five-year outcomes from the EMPOWER-Lung 1 trial, which confirmed the durable survival benefit of Libtayo as monotherapy in advanced NSCLC. Together, the data provide compelling evidence of Libtayo’s role in transforming long-term outcomes for patients with advanced lung cancer.